Zenas BioPharma, Inc. (ZBIO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ZBIO
- Company Zenas BioPharma, Inc.
- Price $12.45
- Changes Percentage -14.14
- Change -2.05
- Day Low $11.65
- Day High $14.61
- Year High $26.25
- Year Low $11.65
- Market Cap $520,297,925
- Price Avg 50 EMA (D) $19.47
- Price Avg 200 EMA (D) $19.47
- Exchange NASDAQ
- Volume 418,910
- Average Volume 177,295
- Open $14.42
- Previous Close $14.5
- EPS -2.97
- PE -4.19
- Earnings Announcement 2024-11-12 12:10:00
- Shares Outstanding $41,790,998
Company brief: ZENAS BIOPHARMA, INC. (ZBIO )
- Healthcare
- Biotechnology
- Mr. Leon Oliver Moulder Jr., M.B.A.
- https://zenasbio.com
- US
- N/A
- 09-13-2024
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.